Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents

A critical issue in the management of relapsing MS (RMS) is the discontinuation of disease-modifying treatments (DMT) due to lack of efficacy, intolerability or impending risks. With new therapeutic agents introduced into the treatment of RMS, immediate- and long-term consequences of sequential drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Korsen, Melanie, Pfeuffer, Steffen, Rolfes, Leoni, Meuth, Sven G., Hartung, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Neurological Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021111/
https://www.ncbi.nlm.nih.gov/pubmed/34999925
http://dx.doi.org/10.1007/s00415-021-10956-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021111/
https://www.ncbi.nlm.nih.gov/pubmed/34999925
http://dx.doi.org/10.1007/s00415-021-10956-1

Ejemplares similares